100 Recruiting Studies Using Cetuximab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Cetuximab
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Building - Phoenix — Phoenix, Arizona
Metastatic Colorectal Cancer
View Study & Checklist ➔Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
📍 MD Anderson Cancer Center — Houston, Texas
Colorectal Cancer
View Study & Checklist ➔Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
📍 City of Hope Medical Center — Duarte, California
Thymoma
View Study & Checklist ➔QTX3046 in Patients With KRAS G12D Mutations
📍 South Texas Accelerated Research Therapeutics, LLC Midwest — Grand Rapids, Michigan
Advanced Solid Tumor
View Study & Checklist ➔A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
📍 Local Institution - 0059 — Los Angeles, California
Metastatic Colorectal Cancer
View Study & Checklist ➔QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
📍 Sarah Cannon Research Institute — Denver, Colorado
Advanced Solid Tumors
View Study & Checklist ➔Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
Metastatic Colon Adenocarcinoma
View Study & Checklist ➔Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
View Study & Checklist ➔Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
BRAF NP_004324.2:p.V600E
View Study & Checklist ➔A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Hospital — Phoenix, Arizona
Neoplasms
View Study & Checklist ➔A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
📍 UCSF — San Francisco, California
Colorectal Cancer Metastatic
View Study & Checklist ➔Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
📍 Beebe South Coastal Health Campus — Millville, Delaware
Colon Adenocarcinoma
View Study & Checklist ➔Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
📍 Local Institution - 010-855-E — Alabaster, Alabama
Advanced Colorectal Cancer
View Study & Checklist ➔Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
📍 Local Institution - 001-826 — Birmingham, Alabama
Advanced Cancer
View Study & Checklist ➔RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Head and Neck Cancer
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Advanced or Metastatic Solid Tumors
View Study & Checklist ➔Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
📍 Massachusetts General Hospital — Boston, Massachusetts
KRAS G12C Mutant Solid Tumors
View Study & Checklist ➔Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Colon Cancer
View Study & Checklist ➔Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Skin Squamous Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
📍 UCLA Healthcare Hematology-Oncology — Santa Monica, California
Solid Tumors
View Study & Checklist ➔Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Head and Neck Cancer
View Study & Checklist ➔Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Colon Adenocarcinoma
View Study & Checklist ➔A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
📍 Highlands Oncology Group, PA — Fayetteville, Arkansas
Carcinoma, Pancreatic Ductal
View Study & Checklist ➔Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Metastatic Colorectal Cancer
View Study & Checklist ➔Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
📍 M D Anderson Cancer Center — Houston, Texas
Chordoma
View Study & Checklist ➔Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
📍 Washington University School of Medicine — St Louis, Missouri
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Head and Neck Cancer
View Study & Checklist ➔Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
📍 Research Site — Tucson, Arizona
Squamous Cell Carcinoma of the Head and Neck
View Study & Checklist ➔A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
📍 Norton Cancer Institute, Downtown — Louisville, Kentucky
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
📍 Research Site — Birmingham, Alabama
Advanced Solid Tumors
View Study & Checklist ➔Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
📍 MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Metastatic Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
📍 Moffitt Cancer Center — Tampa, Florida
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
Colo-rectal Cancer
View Study & Checklist ➔Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
📍 UCSF Medical Center at Mission Bay — San Francisco, California
Breast Cancer
View Study & Checklist ➔Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
BRAF V600E Negative
View Study & Checklist ➔Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
📍 The University of Arizona Cancer Center — Tucson, Arizona
Oropharyngeal Carcinoma (OPC)
View Study & Checklist ➔Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
📍 Washington University School of Medicine — St Louis, Missouri
Kidney Transplant Recipient
View Study & Checklist ➔IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Relapsed Solid Tumor Malignancies
View Study & Checklist ➔ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
📍 MD Anderson Cancer Center — Houston, Texas
Dynamic Tumor Resistance
View Study & Checklist ➔Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study of AUBE00 in Patients With Solid Tumors
📍 South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
Solid Tumors
View Study & Checklist ➔BBO-11818 in Adult Subjects With KRAS Mutant Cancer
📍 The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
📍 Arizona Oncology Associates — Tucson, Arizona
Cancer
View Study & Checklist ➔A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
📍 Moffitt Cancer Center ( Site 0261) — Tampa, Florida
Advanced Solid Tumors
View Study & Checklist ➔Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
📍 Vista Oncology — Olympia, Washington
Left-sided Colorectal Cancer
View Study & Checklist ➔Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Metastatic Colorectal Carcinoma
View Study & Checklist ➔Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
📍 Tower Cancer Research Foundation — Beverly Hills, California
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
View Study & Checklist ➔Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
📍 UPMC Hillman Cancer Center - Radiation Oncology — Pittsburgh, Pennsylvania
Squamous Cell Carcinoma
View Study & Checklist ➔Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Locally Recurrent Skin Squamous Cell Carcinoma
View Study & Checklist ➔A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Metastatic Head-and-neck Squamous-cell Carcinoma
View Study & Checklist ➔Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Head and Neck Neoplasms
View Study & Checklist ➔FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Rhabdomyosarcoma
View Study & Checklist ➔Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Metastatic Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Metastatic Colorectal Cancer
View Study & Checklist ➔A Study of ASP3082 in Adults With Advanced Solid Tumors
📍 City of Hope National Medical Center — Duarte, California
Solid Tumor
View Study & Checklist ➔Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
📍 Ironwood Cancer and Research Centers — Chandler, Arizona
Colorectal Cancer
View Study & Checklist ➔A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
📍 START Los Angeles — Los Angeles, California
Solid Tumor
View Study & Checklist ➔A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
📍 The Angeles Clinic and Research Institute — Los Angeles, California
Solid Tumors
View Study & Checklist ➔A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
📍 Palo Verde Hematology Oncology — Glendale, Arizona
Colorectal Neoplasms
View Study & Checklist ➔A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
📍 Research Site — Orlando, Florida
Cancer
View Study & Checklist ➔A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
📍 Cedars-Sinai Medical Center — Los Angeles, California
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
📍 Dana-Farber/Massachusetts General Hospital, Inc — Boston, Massachusetts
Colorectal Cancer
View Study & Checklist ➔A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Colorectal Neoplasms
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
📍 Johns Hopkins Hospital — Baltimore, Maryland
Advanced Solid Malignancies
View Study & Checklist ➔FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
📍 University of Southern California — La Jolla, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
📍 Brigham and Women's Hospital — Boston, Massachusetts
Head and Neck Cancer
View Study & Checklist ➔A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
📍 John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Advanced Malignant Tumors
View Study & Checklist ➔Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
📍 Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
📍 Mayo Clinic, Phoenix — Phoenix, Arizona
KRAS G12C Mutation
View Study & Checklist ➔QTX3034 in Patients With KRAS G12D Mutation
📍 UCLA Hematology/Oncology — Los Angeles, California
Solid Tumors
View Study & Checklist ➔A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
📍 START- Los Angeles — Los Angeles, California
Pancreatic Ductal Adenocarcinoma (PDAC)
View Study & Checklist ➔FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Advanced Solid Tumor
View Study & Checklist ➔A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Squamous Cell Carcinoma of Head and Neck
View Study & Checklist ➔Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
HPV-Negative Squamous Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
📍 Mayo Clinic Hospital — Phoenix, Arizona
Solid Tumors
View Study & Checklist ➔MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
📍 City of Hope — Duarte, California
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Colorectal Cancer
View Study & Checklist ➔A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
📍 Rutgers Cancer Institute of New Jersey ( Site 0052) — New Brunswick, New Jersey
Malignant Neoplasm
View Study & Checklist ➔A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
📍 City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
Advanced Breast Cancer
View Study & Checklist ➔A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
📍 Clermont Oncology Center ( Site 0041) — Clermont, Florida
Lung Neoplasm Malignant
View Study & Checklist ➔Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
📍 Sanford Worthington Medical Center — Worthington, Minnesota
HPV-unrelated Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
📍 University of Alabama at Birmingham — Birmingham, Alabama
Carcinoma, Squamous Cell
View Study & Checklist ➔Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Advanced Solid Tumors
View Study & Checklist ➔Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
📍 Vanderbilt University Medical Center — Nashville, Tennessee
SCC - Squamous Cell Carcinoma
View Study & Checklist ➔A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
📍 GSK Investigational Site — Stanford, California
Neoplasms
View Study & Checklist ➔KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
📍 Clermont Oncology Center ( Site 0041) — Clermont, Florida
Malignant Neoplasm
View Study & Checklist ➔A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Head and Neck Cancer
View Study & Checklist ➔A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
📍 Christiana Care Health System - Newark- Site Number : 8400011 — Newark, Delaware
Solid Tumor
View Study & Checklist ➔Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
📍 MD Anderson Cancer Center — Houston, Texas
Advanced Colorectal Cancer
View Study & Checklist ➔Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
📍 PanOncology — Manati,
Colorectal Cancer
View Study & Checklist ➔A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
Metastatic Colorectal Cancer
View Study & Checklist ➔A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
📍 Local Institution - 0005 — Phoenix, Arizona
Solid Tumors
View Study & Checklist ➔A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
📍 START Los Angeles — Los Angeles, California
Colorectal Cancer
View Study & Checklist ➔